Literature DB >> 6374010

Fibronectin enhances the opsonic and protective activity of monoclonal and polyclonal antibody against group B streptococci.

H R Hill, A O Shigeoka, N H Augustine, D Pritchard, J L Lundblad, R S Schwartz.   

Abstract

We have investigated the opsonic and protective effects of fibronectin (FN) against type III group B streptococci. When used by itself, the FN failed to promote actual internalization of group B organisms. The addition of FN to group B streptococci that had been preopsonized in an immunoglobulin preparation modified for intravenous use ( IgIV ) or a type-specific, murine monoclonal antibody of IgG isotype markedly enhanced interaction with human polymorphonuclear leukocytes (PMN). A similar enhanced effect was observed when the FN was combined with type-specific monoclonal antibody preparations of IgM and, surprisingly, IgA isotype. Preincubation experiments indicated that the major effect was upon the PMN rather than directly on the bacteria, but we could not demonstrate an effect of FN on cell surface receptors for the Fc fragment of Ig or C3b using rosetting techniques. In addition to enhancing the in vitro opsonic activity of Ig, the FN significantly increased the protective effect of the polyclonal and monoclonal Ig preparations in an animal model of neonatal group B streptococcal disease. Thus, FN appears to have a critical role in the host defense mechanisms against group B streptococci.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6374010      PMCID: PMC2187317          DOI: 10.1084/jem.159.6.1618

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Evaluation of group B streptococcal opsonins by radiolabeled bacterial uptake.

Authors:  C D Allred; A O Shigeoka; H R Hill
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

2.  A low-viscosity epoxy resin embedding medium for electron microscopy.

Authors:  A R Spurr
Journal:  J Ultrastruct Res       Date:  1969-01

Review 3.  The structure and biologic activities of plasma fibronectin.

Authors:  M W Mosesson; D L Amrani
Journal:  Blood       Date:  1980-08       Impact factor: 22.113

4.  Development of functional complement receptors during in vitro maturation of human monocytes into macrophages.

Authors:  S L Newman; R A Musson; P M Henson
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

5.  Fibronectin (cold insoluble globulin) in the neonate.

Authors:  D R Barnard; M M Arthur
Journal:  J Pediatr       Date:  1983-03       Impact factor: 4.406

6.  A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction.

Authors:  D D Schroeder; D L Tankersley; J L Lundblad
Journal:  Vox Sang       Date:  1981       Impact factor: 2.144

7.  Adherence of group A streptococci to fibronectin on oral epithelial cells.

Authors:  W A Simpson; E H Beachey
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

8.  The use of lead citrate at high pH as an electron-opaque stain in electron microscopy.

Authors:  E S REYNOLDS
Journal:  J Cell Biol       Date:  1963-04       Impact factor: 10.539

9.  Receptors for cold-insoluble globulin (plasma fibronectin) on human monocytes.

Authors:  M P Bevilacqua; D Amrani; M W Mosesson; C Bianco
Journal:  J Exp Med       Date:  1981-01-01       Impact factor: 14.307

10.  IgA-dependent, monocyte-mediated, antibacterial activity.

Authors:  G H Lowell; L F Smith; J M Griffiss; B L Brandt
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  9 in total

1.  The potential use of monoclonal antibodies as therapeutic modalities in neonatal infection.

Authors:  H R Hill; L A Gonzales; D K Kelsey; H V Raff
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  The immunopathology of acute experimental allergic encephalomyelitis. V. A light microscopic and ultrastructural immunohistochemical analysis of fibronectin and fibrinogen.

Authors:  R A Sobel; E E Schneeberger; R B Colvin
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

Review 3.  Monoclonal antibodies for the diagnosis of infectious diseases.

Authors:  M C Harris
Journal:  Indian J Pediatr       Date:  1987 Jul-Aug       Impact factor: 1.967

4.  Interaction of soluble fibronectin with group B streptococci.

Authors:  K M Butler; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

5.  Fibronectin in polyethylene glycol precipitates: evidence for a role in immune complexes.

Authors:  J S Coppock; D L Scott; S D Carter; T M Moreland; M W Robinson
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

6.  Effects of fibronectin and group B streptococci on tumour necrosis factor-alpha production by human culture-derived macrophages.

Authors:  E B Peat; N H Augustine; W K Drummond; J F Bohnsack; H R Hill
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

7.  Decreased plasma fibronectin concentrations in preterm infants with septicaemia.

Authors:  M P Dyke; K D Forsyth
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

8.  Mechanism of fibronectin enhancement of group B streptococcal phagocytosis by human neutrophils and culture-derived macrophages.

Authors:  H R Hill; N H Augustine; P A Williams; E J Brown; J F Bohnsack
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

9.  The FUT2 Variant c.461G>A (p.Trp154*) Is Associated With Differentially Expressed Genes and Nasopharyngeal Microbiota Shifts in Patients With Otitis Media.

Authors:  Christina L Elling; Melissa A Scholes; Sven-Olrik Streubel; Eric D Larson; Todd M Wine; Tori C Bootpetch; Patricia J Yoon; Jennifer M Kofonow; Samuel P Gubbels; Stephen P Cass; Charles E Robertson; Herman A Jenkins; Jeremy D Prager; Daniel N Frank; Kenny H Chan; Norman R Friedman; Allen F Ryan; Regie Lyn P Santos-Cortez
Journal:  Front Cell Infect Microbiol       Date:  2022-01-14       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.